United States-based institutional shareholders reportedly control 88% of McKesson Corporation (MCK). Despite complexities in Q2 outlook, McKesson has experienced a drive, hitting a 52-week high. Much of the growth has been attributed to the company's strategic decisions. The sale of Canadian businesses Rexall and Well.ca to Birch Hill Equity Partners perhaps charms some investors, although its shares dipped following the announcement. McKesson also plans to acquire controlling interest in Florida Cancer Specialists & Research Institute’s Core Ventures, despite experiencing supply and demand issues for certain drugs.
Several reports praise McKesson as a worthy long-term value and momentum stock. Expert analysts maintain it as a 'buy.' The recent performance displayed strong revenue growth while its earnings slightly dipped. McKesson's 2024 Q4 results, though softer than expected, do not overshadow its credibility. The company has recently been involved in a significant transaction, buying a stake in Florida's Cancer Chain for $2.49 Billion. There has been a circular flow of MCK shares, passing between the CEO, directors, and institutional investors. Sector analysis indicates that despite the stock's dip, McKessons has outperformed the market.
Mckesson Corporation MCK News Analytics from Thu, 04 Jan 2024 08:00:00 GMT to Sat, 07 Sep 2024 15:21:22 GMT - Rating 8 - Innovation 3 - Information 6 - Rumor -5
